Oral bioavailability enhancement of agomelatine by loading into nanostructured lipid carriers: Peyer’s patch targeting approach

Agomelatine (AGM) is a new antidepressant drug with a novel mechanism of action and fewer side effects compared with older antidepressants. AGM is a melatonin receptor (MT1 and MT2) agonist and 5-hydroxytryptamine receptor (5-HT(2C)) antagonist. In the present study, the enhancement of the oral bioa...

Descripción completa

Detalles Bibliográficos
Autores principales: Prajapati, Jagruti B, Verma, Sneha D, Patel, Amit A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2018
Materias:
Short Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5863623/
https://www.ncbi.nlm.nih.gov/pubmed/29593392
http://dx.doi.org/10.2147/IJN.S124703

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5863623/
https://www.ncbi.nlm.nih.gov/pubmed/29593392
http://dx.doi.org/10.2147/IJN.S124703

Ejemplares similares